Vapotherm, Inc. (NYSE: VAPO), a global medical technology
company focused on the development and commercialization of its
proprietary Hi-VNI® Technology products that are used to treat
patients of all ages suffering from respiratory distress, today
announced its financial and operating results for the third quarter
ended September 30, 2019.
Third Quarter 2019 Highlights
- Revenue for the third quarter of 2019 was $10.8 million, a
15.1% increase over the prior year period.
- Worldwide installed base of Precision Flow units grew by 18.5%
compared to the third quarter of 2018.
- Disposable revenue increased 24.3% compared to the third
quarter of 2018.
- Gross margin was 44.5% compared to 38.5% in the third quarter
of 2018.
“Our performance during the third quarter was highlighted by 24%
worldwide disposable revenue growth and significant gross margin
expansion. Despite generally positive trends in the business,
revenue came in below our expectations as a result of lower U.S.
capital revenue,” said Joe Army, President and CEO of Vapotherm.
“For the remainder of 2019, we are focused on continuing to expand
our installed base, driving disposable revenue growth and preparing
for the launch of new products.”
Results for the Three Months Ended September 30, 2019
The following table reflects the Company’s net revenue for the
three months ended September 30, 2019 and 2018:
Three Months Ended September
30,
2019
2018
Change
(unaudited)
(in thousands, except
percentages)
Amount
% of Revenue
Amount
% of Revenue
$
%
Revenue
Capital (product & lease revenue)
$
2,518
23.3
%
$
2,707
28.8
%
$
(189
)
-7.0
%
Disposable
7,827
72.4
%
6,297
67.1
%
1,530
24.3
%
Service and Other
464
4.3
%
385
4.1
%
79
20.5
%
Total Revenue
$
10,809
100.0
%
$
9,389
100.0
%
$
1,420
15.1
%
Revenue for the third quarter of 2019 was $10.8 million, a 15.1%
increase over the third quarter of 2018. Total capital revenue,
including both product sales and lease revenue, decreased 7.0% over
the third quarter of 2018 primarily as a result of fewer sales and
leases of our Precision Flow units and lower average selling prices
in the U.S. Total disposable revenue increased 24.3% year over
year, primarily driven by an increase in the worldwide installed
base of Precision Flow units, increased average selling prices
worldwide and, to a lesser extent, higher utilization rates in our
International markets. Disposable revenue as a percentage of total
revenue for the third quarter of 2019 and 2018 was 72.4% and 67.1%,
respectively.
Revenue information by geography is summarized as follows:
Three Months Ended September
30,
2019
2018
Change
(unaudited)
(in thousands, except
percentages)
Amount
% of Revenue
Amount
% of Revenue
$
%
United States
$
8,035
74.3
%
$
7,537
80.3
%
$
498
6.6
%
International
2,774
25.7
%
1,852
19.7
%
922
49.8
%
Total Revenue
$
10,809
100.0
%
$
9,389
100.0
%
$
1,420
15.1
%
U.S. revenue growth in the third quarter of 2019 was driven by
an increase in disposable sales due to a higher installed base of
Precision Flow units and higher average selling prices, partially
offset by fewer sales and leases of our Precision Flow units and
lower average selling prices. International revenue growth in the
third quarter was primarily driven by an increase in disposable
sales due to a higher installed base of Precision Flow units,
higher average selling prices and higher utilization rates and, to
a lesser extent, increases in service and other revenue from our
U.K. business.
Our total installed base of Precision Flow units at the end of
the third quarter of 2019 was 15,813 units, comprised of 11,475 and
4,338 units in the U.S. and International markets, respectively.
This represents a 18.5% increase over our installed base at the end
of the third quarter of 2018. We sold and leased 316 and 162
Precision Flow units in the U.S. and International markets,
respectively, in the third quarter of 2019. In the third quarter of
2019, we sold 56,231 and 22,943 disposables in the U.S. and
International markets, respectively.
Gross profit for the third quarter of 2019 was $4.8 million, an
increase of $1.2 million over the third quarter of 2018. Gross
margin was 44.5% in the third quarter of 2019 compared to 38.5% in
the third quarter of 2018. The increase in gross margin was driven
by a decrease in disposable component costs in comparison to the
third quarter of 2018, reduced overhead rates per unit, a favorable
sales mix of disposables and increased average selling prices.
Operating expenses were $16.5 million in the third quarter of
2019, an increase of $4.1 million as compared to $12.3 million in
the same period last year. The increase in operating expenses was
primarily a result of increased headcount and employee-related
expenses, product development costs, legal and consulting fees,
public company related expenses and increased investments in sales
and marketing initiatives.
Net loss for the third quarter of 2019 was $12.8 million, or
$0.65 per share, compared to $9.5 million, or $10.90 per share, in
the third quarter of 2018. Net loss per share was based on
19,531,153 and 875,453 weighted average shares outstanding for the
third quarter of 2019 and 2018, respectively.
Adjusted EBITDA was ($10.7) million for the third quarter of
2019 as compared to ($8.0) million for the third quarter of 2018.
The $2.7 million increase in Adjusted EBITDA loss in the third
quarter of 2019 was primarily due to higher operating expenses,
partially offset by higher gross profit.
Cash Position
Cash and cash equivalents were $83.5 million as of September 30,
2019 compared to $58.2 million as of December 31, 2018 and $46.1
million as of June 30, 2019. During the quarter, the Company
completed a public offering of its common stock, raising net
proceeds of $48.3 million.
Fiscal 2019 Outlook
For fiscal 2019, we expect revenue to be between $47.1 million
and $47.6 million, which represents a year-over-year increase of
11% to 12%, a decrease from our prior guidance of $49.0 million and
$51.0 million due to lower U.S. capital revenue expectations.
In the fourth quarter of 2019, we expect revenue in the range of
$12.0 million to $12.5 million, an anticipated year-over-year
increase of between 3% to 7%.
For fiscal 2019, we expect gross margin to be in the range of
43% to 44%, an increase from our prior guidance of 42.5% to
43.5%.
For fiscal 2019, we expect operating expenses to be in the range
of $68.0 million to $70.0 million.
Conference Call
Management will host a conference call at 4:30 p.m. Eastern Time
on November 5, 2019 to discuss the results of the quarter with a
question and answer session. To listen to the conference call on
your telephone, please dial (877) 201-0168 for U.S. callers, or
(647) 788-4901 for international callers, approximately ten minutes
prior to start time and reference conference code 1579489. To
listen to a live webcast, please visit the Investors section of the
Vapotherm website at:
http://investors.vapotherm.com/events-and-presentations/events. The
webcast replay will be available on the Vapotherm website for 90
days following the completion of the call. A replay of this
conference call will be available over the phone through November
12, 2019 by dialing (800) 585-8367 in the U.S. or (416) 621-4642
outside of the U.S. The replay access code is 1579489.
Website Information
Vapotherm routinely posts important information for investors on
the Investor Relations section of its website,
http://investors.vapotherm.com/. Vapotherm intends to use this
website as a means of disclosing material, non-public information
and for complying with Vapotherm’s disclosure obligations under
Regulation FD. Accordingly, investors should monitor the Investor
Relations section of Vapotherm’s website, in addition to following
Vapotherm’s press releases, Securities and Exchange Commission
filings, public conference calls, presentations and webcasts. The
information contained on, or that may be accessed through,
Vapotherm’s website is not incorporated by reference into, and is
not a part of, this document.
Non-GAAP Financial Measures
This press release includes the non-GAAP financial measure of
EBITDA and Adjusted EBITDA, which differ from financial measures
calculated in accordance with U.S. generally accepted accounting
principles (“GAAP”). EBITDA in this press release represents net
loss less interest expense, net and depreciation and amortization.
Adjusted EBITDA in this release represents EBITDA as adjusted for
the impact of foreign currency loss or gain, the change in fair
value of warrant liabilities, and stock-based compensation expense.
The Company has reconciled these non-GAAP financial measures with
the most directly comparable GAAP financial measures in tables
accompanying this release.
Adjusted EBITDA is presented because the Company believes it is
a useful indicator of its operating performance. Management uses
the measure principally as a measure of the Company’s operating
performance and for planning purposes, including the preparation of
the Company’s annual operating budget and financial projections.
The Company believes this measure is useful to investors as
supplemental information because it is frequently used by analysts,
investors and other interested parties to evaluate companies in its
industry. The Company believes Adjusted EBITDA is useful to its
management and investors as a measure of comparative operating
performance from period to period.
Adjusted EBITDA is a non-GAAP financial measure and should not
be considered as an alternative to, or superior to, net income or
loss as a measure of financial performance or cash flows from
operations as a measure of liquidity, or any other performance
measure derived in accordance with GAAP. It should not be construed
to imply that the Company’s future results will be unaffected by
unusual or non-recurring items. In addition, the measure is not
intended to be a measure of free cash flow for management’s
discretionary use, as it does not reflect certain cash requirements
such as tax payments, debt service requirements, capital
expenditures and certain other cash costs that may recur in the
future. Adjusted EBITDA contain certain other limitations,
including the failure to reflect our capital expenditures, cash
requirements for working capital needs and cash costs to replace
assets being depreciated and amortized. In evaluating Adjusted
EBITDA, you should be aware that in the future the Company may
incur expenses that are the same as or similar to some of the
adjustments in this presentation. The Company’s presentation of
Adjusted EBITDA should not be construed to imply that its future
results will be unaffected by any such adjustments. Management
compensates for these limitations by primarily relying on the
Company’s GAAP results in addition to using Adjusted EBITDA on a
supplemental basis. The Company’s definition of this measure is not
necessarily comparable to other similarly titled captions of other
companies due to different methods of calculation.
About Vapotherm
Vapotherm, Inc. is a publicly traded developer and manufacturer
of advanced respiratory technology based in Exeter, New Hampshire,
USA. The Company develops innovative, comfortable, non-invasive
technologies for respiratory support of patients with chronic or
acute breathing disorders. Over 2.0 million patients have been
treated with Vapotherm Hi-VNI Technology. Hi-VNI Technology is
mask-free noninvasive ventilatory support for spontaneously
breathing patients and is a front-line tool for relieving
respiratory distress—including hypercapnia, hypoxemia, and dyspnea.
It allows for the fast, safe treatment of undifferentiated
respiratory distress with one tool. Hi-VNI Technology’s mask-free
interface delivers optimally conditioned breathing gases, making it
comfortable for patients and reducing the risks associated with
mask therapies. While being treated, patients can talk, eat, drink
and take oral medication. For more information, visit
www.vapotherm.com.
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995, including statements about the
expansion of our installed base, driving disposable revenue growth,
the potential launch of new products and full year or quarterly
revenue, gross margin, and operating expense guidance. In some
cases, you can identify forward-looking statements by terms such as
‘‘expect,’’ “guide” or “typically” or the negative of these terms
or other similar expressions, although not all forward-looking
statements contain these words. Each forward-looking statement is
subject to risks and uncertainties that could cause actual results
to differ materially from those expressed or implied in such
statement. Applicable risks and uncertainties include, but are not
limited to the following: Vapotherm has incurred losses in the past
and may be unable to achieve or sustain profitability in the
future, Vapotherm may need to raise additional capital to fund its
existing commercial operations, develop and commercialize new
products, and expand its operations, Vapotherm’s dependence on
sales generated from its Precision Flow systems, competition from
multi-national corporations who have significantly greater
resources than Vapotherm and are more established in the
respiratory market, the ability for Precision Flow systems to gain
increased market acceptance, its inexperience directly marketing
and selling its products, the potential loss of one or more
suppliers, Vapotherm’s susceptibility to seasonal fluctuations,
Vapotherm’s failure to comply with applicable United States and
foreign regulatory requirements, the failure to obtain U.S. Food
and Drug Administration or other regulatory authorization to market
and sell future products or its inability to secure and maintain
patent or other intellectual property protection for its products
and the other risks and uncertainties included under the heading
“Risk Factors” in Vapotherm’s Annual Report on Form 10-K for the
fiscal year ended December, 31, 2018, as filed with the Securities
and Exchange Commission on March 22, 2019, and in any subsequent
filings with the Securities and Exchange Commission. The
forward-looking statements contained in this press release reflect
Vapotherm’s views as of the date hereof, and Vapotherm does not
assume and specifically disclaims any obligation to update any
forward-looking statements whether as a result of new information,
future events or otherwise, except as required by law.
Financial Statements:
Vapotherm, Inc. UNAUDITED CONDENSED
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (In thousands, except
share and per share amounts)
Three Months Ended September
30,
Nine Months Ended September
30,
2019
2018
2019
2018
Net revenue
$
10,809
$
9,389
$
35,094
$
30,691
Cost of goods sold
5,999
5,775
19,646
18,737
Gross profit
4,810
3,614
15,448
11,954
Operating expenses
Research and development
3,280
1,766
9,720
6,074
Sales and marketing
9,193
7,757
27,786
24,331
General and administrative
3,978
2,804
13,389
7,789
Loss on disposal of property and
equipment
-
17
-
59
Total operating expenses
16,451
12,344
50,895
38,253
Loss from operations
(11,641
)
(8,730
)
(35,447
)
(26,299
)
Other (expense) income
Foreign currency loss
(28
)
-
(37
)
(2
)
Interest income
242
8
658
21
Interest expense
(1,338
)
(908
)
(3,783
)
(2,022
)
Loss on extinguishment of debt
-
-
-
(1,842
)
Gain on change in fair value of warrant
liabilities
-
171
-
553
Net loss
$
(12,765
)
$
(9,459
)
$
(38,609
)
$
(29,591
)
Accretion of preferred stock to redemption
value
-
(81
)
-
(81
)
Net loss attributable to common
stockholders
$
(12,765
)
$
(9,540
)
$
(38,609
)
$
(29,672
)
Net loss per share attributable to common
stockholders - basic and diluted
$
(0.65
)
$
(10.90
)
$
(2.16
)
$
(35.59
)
Other comprehensive loss, net of tax:
Foreign currency translation
adjustments
(72
)
-
(70
)
-
Total other comprehensive loss
$
(72
)
$
-
$
(70
)
$
-
Total comprehensive loss
$
(12,837
)
$
(9,459
)
$
(38,679
)
$
(29,591
)
Weighted-average number of shares used in
calculating net loss per share, basic and diluted
19,531,153
875,453
17,854,730
833,738
VAPOTHERM, INC. UNAUDITED CONDENSED
CONSOLIDATED BALANCE SHEETS (In thousands, except share
amounts)
September 30, 2019
December 31, 2018
Assets
Current assets
Cash and cash equivalents
$
83,522
$
58,223
Accounts receivable, net
6,848
7,107
Inventory
10,844
13,710
Prepaid expenses and other current
assets
2,067
2,683
Total current assets
103,281
81,723
Property and equipment, net
14,307
13,416
Restricted cash
1,852
1,799
Goodwill
539
-
Intangible assets, net
351
-
Other long-term assets
406
308
Total assets
$
120,736
$
97,246
Liabilities and Stockholders’
Equity
Current liabilities
Accounts payable
$
1,644
$
3,148
Contract liabilities
123
79
Accrued expenses and other current
liabilities
8,888
7,653
Short-term line of credit
2,912
3,163
Total current liabilities
13,567
14,043
Long-term loans payable
41,716
31,317
Deferred income tax liability
90
-
Other long-term liabilities
225
325
Total liabilities
55,598
45,685
Commitments and contingencies (Note 7)
Stockholders' equity
Preferred stock ($0.001 par value)
25,000,000 shares authorized; no shares issued and outstanding as
of September 30, 2019 and December 31, 2018
-
-
Common stock ($0.001 par value)
175,000,000 shares authorized as of September 30, 2019 and December
31, 2018, 20,801,613 and 16,782,837 shares issued and outstanding
as of September 30, 2019 and December 31, 2018, respectively
21
17
Additional paid-in capital
318,178
265,926
Accumulated deficit
(252,991
)
(214,382
)
Accumulated other comprehensive loss
(70
)
-
Total stockholders' equity
65,138
51,561
Total liabilities and stockholders’
equity
$
120,736
$
97,246
VAPOTHERM, INC. UNAUDITED CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands)
Nine Months Ended September
30,
2019
2018
(unaudited)
Cash flows from operating activities
Net loss
$
(38,609
)
$
(29,591
)
Adjustments to reconcile net loss to net
cash used in operating activities
Depreciation and amortization
2,219
1,561
Stock-based compensation expense
2,755
367
Loss on disposal of property and
equipment
112
306
Provision for bad debts
77
101
Loss on extinguishment of debt
-
1,842
Amortization of discount on debt
171
95
Change in fair value of warrants
-
(553
)
Changes in operating assets and
liabilities, net of acquisition:
Accounts receivable
616
896
Inventory
3,382
(1,082
)
Prepaid expenses and other assets
528
(1,011
)
Accounts payable
(1,551
)
(336
)
Contract liabilities
(31
)
2
Accrued expenses and other current
liabilities
1,801
(1,193
)
Net cash used in operating activities
(28,530
)
(28,596
)
Cash flows from investing activities
Acquisition of business, net of cash
acquired
(1,560
)
-
Purchases of property and equipment
(3,132
)
(3,997
)
Net cash used in investing activities
(4,692
)
(3,997
)
Cash flows from financing activities
Issuance of common stock in connection
with public offering of common stock, net of issuance costs
48,308
-
Proceeds on loans
10,500
30,374
Repayment of loans payable
-
(20,000
)
Debt issuance costs
(322
)
-
Short-term line of credit
(260
)
(1,333
)
Proceeds from issuance of redeemable
convertible preferred stock, net
-
9,919
Proceeds from exercise of stock options
and purchase of restricted stock
374
325
Net cash provided by financing
activities
58,600
19,285
Effect of exchange rate changes on cash,
cash equivalents and restricted cash
(26
)
-
Net increase (decrease) in cash, cash
equivalents and restricted cash
25,352
(13,308
)
Cash, cash equivalents and restricted
cash
Beginning of period
60,022
28,360
End of period
$
85,374
$
15,052
Supplemental disclosures of cash flow
information
Interest paid during the period
$
3,563
$
2,035
Issuance of warrants in conjunction with
debt draw down
$
293
$
-
Property and equipment purchases in
accrued expenses
$
222
$
472
Non-GAAP Financial Measures The
following tables contain a reconciliation of net loss to Adjusted
EBITDA for the three months ended September 30, 2019 and 2018,
respectively.
Three Months Ended September
30,
Amount
Change
2019
2018
$
%
(unaudited)
(in thousands, except
percentages)
Net loss
$
(12,765
)
$
(9,459
)
$
(3,306
)
-35.0
%
Interest expense, net
1,096
900
196
-21.8
%
Depreciation and amortization
812
570
242
-42.5
%
EBITDA
$
(10,857
)
$
(7,989
)
$
(2,868
)
-35.9
%
Foreign currency
28
-
28
100.0
%
Change in fair value of warrant
liabilities
-
(171
)
171
-100.0
%
Stock-based compensation
140
133
7
-5.3
%
Adjusted EBITDA
$
(10,689
)
$
(8,027
)
$
(2,662
)
-33.2
%
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191105005998/en/
Mark Klausner or Mike Vallie, Westwicke, an ICR Company,
ir@vtherm.com, +1 (603) 658-0011
Vapotherm (NYSE:VAPO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Vapotherm (NYSE:VAPO)
Historical Stock Chart
From Mar 2023 to Mar 2024